nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—BCHE—peripheral nervous system neoplasm	0.55	1	CbGaD
Galantamine—CHRNA9—cochlear duct of membranous labyrinth—peripheral nervous system neoplasm	0.039	0.265	CbGeAlD
Galantamine—CHRNA9—cochlea—peripheral nervous system neoplasm	0.0198	0.134	CbGeAlD
Galantamine—CHRNA9—internal ear—peripheral nervous system neoplasm	0.0187	0.127	CbGeAlD
Galantamine—BCHE—Cisplatin—peripheral nervous system neoplasm	0.0118	0.433	CbGbCtD
Galantamine—CHRNB3—pons—peripheral nervous system neoplasm	0.0102	0.0688	CbGeAlD
Galantamine—CHRNA10—internal ear—peripheral nervous system neoplasm	0.00828	0.0562	CbGeAlD
Galantamine—CHRNA4—cochlear duct of membranous labyrinth—peripheral nervous system neoplasm	0.00775	0.0525	CbGeAlD
Galantamine—CHRNB3—ganglion—peripheral nervous system neoplasm	0.0052	0.0353	CbGeAlD
Galantamine—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0045	0.165	CbGbCtD
Galantamine—CHRNA6—ganglion—peripheral nervous system neoplasm	0.00434	0.0294	CbGeAlD
Galantamine—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.00418	0.154	CbGbCtD
Galantamine—CHRNG—tongue—peripheral nervous system neoplasm	0.00405	0.0274	CbGeAlD
Galantamine—CHRNA4—cochlea—peripheral nervous system neoplasm	0.00392	0.0266	CbGeAlD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—NF2—peripheral nervous system neoplasm	0.00319	0.0716	CbGpPWpGaD
Galantamine—CHRNA1—tongue—peripheral nervous system neoplasm	0.00268	0.0182	CbGeAlD
Galantamine—CHRNB3—trigeminal ganglion—peripheral nervous system neoplasm	0.00255	0.0173	CbGeAlD
Galantamine—CHRNA5—Nicotine Activity on Dopaminergic Neurons—TH—peripheral nervous system neoplasm	0.00248	0.0558	CbGpPWpGaD
Galantamine—CHRNB3—brainstem—peripheral nervous system neoplasm	0.00226	0.0153	CbGeAlD
Galantamine—CHRNG—trigeminal ganglion—peripheral nervous system neoplasm	0.00201	0.0136	CbGeAlD
Galantamine—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00192	0.0706	CbGbCtD
Galantamine—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00189	0.0694	CbGbCtD
Galantamine—CHRNA6—brainstem—peripheral nervous system neoplasm	0.00189	0.0128	CbGeAlD
Galantamine—CHRNA6—Nicotine Activity on Dopaminergic Neurons—TH—peripheral nervous system neoplasm	0.00188	0.0423	CbGpPWpGaD
Galantamine—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00176	0.0647	CbGbCtD
Galantamine—CHRNB2—Nicotine Activity on Dopaminergic Neurons—TH—peripheral nervous system neoplasm	0.00166	0.0372	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—NF2—peripheral nervous system neoplasm	0.0016	0.036	CbGpPWpGaD
Galantamine—CHRNA7—ganglion—peripheral nervous system neoplasm	0.00158	0.0107	CbGeAlD
Galantamine—CHRNA4—nerve—peripheral nervous system neoplasm	0.00158	0.0107	CbGeAlD
Galantamine—CHRNA4—ganglion—peripheral nervous system neoplasm	0.00156	0.0106	CbGeAlD
Galantamine—ACHE—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—peripheral nervous system neoplasm	0.00152	0.0341	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.00126	0.0284	CbGpPWpGaD
Galantamine—CHRNB2—trigeminal ganglion—peripheral nervous system neoplasm	0.00122	0.0083	CbGeAlD
Galantamine—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.0012	0.0441	CbGbCtD
Galantamine—CHRNA3—Nicotine Activity on Dopaminergic Neurons—TH—peripheral nervous system neoplasm	0.00119	0.0268	CbGpPWpGaD
Galantamine—CHRNB2—parotid gland—peripheral nervous system neoplasm	0.00116	0.00783	CbGeAlD
Galantamine—CHRNB3—cerebellum—peripheral nervous system neoplasm	0.00111	0.00756	CbGeAlD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.000994	0.0223	CbGpPWpGaD
Galantamine—CHRNA6—cerebellum—peripheral nervous system neoplasm	0.00093	0.00631	CbGeAlD
Galantamine—CHRNA4—Nicotine Activity on Dopaminergic Neurons—TH—peripheral nervous system neoplasm	0.000923	0.0207	CbGpPWpGaD
Galantamine—ACHE—trigeminal ganglion—peripheral nervous system neoplasm	0.000891	0.00604	CbGeAlD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.000863	0.0194	CbGpPWpGaD
Galantamine—ACHE—Biogenic Amine Synthesis—TH—peripheral nervous system neoplasm	0.000861	0.0194	CbGpPWpGaD
Galantamine—ACHE—Synthesis, secretion, and deacylation of Ghrelin—BCHE—peripheral nervous system neoplasm	0.000829	0.0186	CbGpPWpGaD
Galantamine—ACHE—Synthesis of PC—BCHE—peripheral nervous system neoplasm	0.000758	0.0171	CbGpPWpGaD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—PTPN11—peripheral nervous system neoplasm	0.00074	0.0166	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.000703	0.0158	CbGpPWpGaD
Galantamine—CHRNA4—brainstem—peripheral nervous system neoplasm	0.000677	0.00459	CbGeAlD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—ERBB2—peripheral nervous system neoplasm	0.000585	0.0131	CbGpPWpGaD
Galantamine—CHRNB2—cerebellum—peripheral nervous system neoplasm	0.000534	0.00362	CbGeAlD
Galantamine—CHRNA9—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000525	0.0118	CbGpPWpGaD
Galantamine—CHRNA3—cerebellum—peripheral nervous system neoplasm	0.000518	0.00351	CbGeAlD
Galantamine—CHRNA2—cerebellum—peripheral nervous system neoplasm	0.000482	0.00327	CbGeAlD
Galantamine—ACHE—Monoamine Transport—TH—peripheral nervous system neoplasm	0.00047	0.0106	CbGpPWpGaD
Galantamine—CYP2D6—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.000468	0.0105	CbGpPWpGaD
Galantamine—CHRNB3—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000459	0.0103	CbGpPWpGaD
Galantamine—CHRNB1—cerebellum—peripheral nervous system neoplasm	0.000448	0.00304	CbGeAlD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—NRAS—peripheral nervous system neoplasm	0.000445	0.01	CbGpPWpGaD
Galantamine—BCHE—trigeminal ganglion—peripheral nervous system neoplasm	0.000438	0.00297	CbGeAlD
Galantamine—CHRNA5—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000435	0.00978	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—NF1—peripheral nervous system neoplasm	0.000435	0.00978	CbGpPWpGaD
Galantamine—CHRNG—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000415	0.00933	CbGpPWpGaD
Galantamine—CHRNA9—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000402	0.00905	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.00039	0.00877	CbGpPWpGaD
Galantamine—ACHE—cerebellum—peripheral nervous system neoplasm	0.000389	0.00264	CbGeAlD
Galantamine—BCHE—brainstem—peripheral nervous system neoplasm	0.000387	0.00263	CbGeAlD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—PTPN11—peripheral nervous system neoplasm	0.000372	0.00836	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000363	0.00817	CbGpPWpGaD
Galantamine—CHRNB3—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000352	0.00791	CbGpPWpGaD
Galantamine—CHRNA4—cerebellum—peripheral nervous system neoplasm	0.000334	0.00226	CbGeAlD
Galantamine—CHRNA5—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000333	0.00749	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000333	0.00749	CbGpPWpGaD
Galantamine—CHRNA6—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.00033	0.00741	CbGpPWpGaD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—HRAS—peripheral nervous system neoplasm	0.000325	0.00731	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000318	0.00715	CbGpPWpGaD
Galantamine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.000306	0.00688	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000299	0.00672	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—ERBB2—peripheral nervous system neoplasm	0.000294	0.00661	CbGpPWpGaD
Galantamine—CHRNB2—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.00029	0.00653	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—TH—peripheral nervous system neoplasm	0.000288	0.00648	CbGpPWpGaD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—AKT1—peripheral nervous system neoplasm	0.000287	0.00646	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000286	0.00643	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000272	0.00611	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000271	0.0061	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000262	0.00589	CbGpPWpGaD
Galantamine—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.00026	0.00584	CbGpPWpGaD
Galantamine—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000257	0.00174	CbGeAlD
Galantamine—CHRNA6—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000253	0.00568	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000248	0.00558	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000242	0.00544	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000231	0.00519	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—BCHE—peripheral nervous system neoplasm	0.000229	0.00514	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000229	0.00514	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000228	0.00512	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.000224	0.00504	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—NRAS—peripheral nervous system neoplasm	0.000224	0.00503	CbGpPWpGaD
Galantamine—ACHE—Glycerophospholipid biosynthesis—BCHE—peripheral nervous system neoplasm	0.000222	0.005	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000222	0.005	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000214	0.0048	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000209	0.0047	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000202	0.00455	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000198	0.00446	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000196	0.00441	CbGpPWpGaD
Galantamine—BCHE—cerebellum—peripheral nervous system neoplasm	0.000191	0.0013	CbGeAlD
Galantamine—CHRNA2—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000187	0.00419	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000185	0.00417	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000185	0.00417	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000177	0.00398	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000175	0.00394	CbGpPWpGaD
Galantamine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.000167	0.00376	CbGpPWpGaD
Galantamine—CHRNA9—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	0.000164	0.00368	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—HRAS—peripheral nervous system neoplasm	0.000164	0.00368	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000162	0.00364	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—BCHE—peripheral nervous system neoplasm	0.00016	0.0036	CbGpPWpGaD
Galantamine—ACHE—Phospholipid metabolism—BCHE—peripheral nervous system neoplasm	0.000155	0.00349	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000152	0.00342	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000151	0.0034	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—BCHE—peripheral nervous system neoplasm	0.00015	0.00338	CbGpPWpGaD
Galantamine—Muscular weakness—Epirubicin—peripheral nervous system neoplasm	0.000147	0.000638	CcSEcCtD
Galantamine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000147	0.000637	CcSEcCtD
Galantamine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000147	0.000637	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000145	0.000631	CcSEcCtD
Galantamine—Ataxia—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.000629	CcSEcCtD
Galantamine—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000145	0.000629	CcSEcCtD
Galantamine—Nausea—Melphalan—peripheral nervous system neoplasm	0.000145	0.000629	CcSEcCtD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—AKT1—peripheral nervous system neoplasm	0.000145	0.00325	CbGpPWpGaD
Galantamine—Dysphagia—Epirubicin—peripheral nervous system neoplasm	0.000144	0.000625	CcSEcCtD
Galantamine—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000144	0.000622	CcSEcCtD
Galantamine—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000143	0.000622	CcSEcCtD
Galantamine—CHRNB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	0.000143	0.00322	CbGpPWpGaD
Galantamine—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000143	0.000621	CcSEcCtD
Galantamine—CHRNA2—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000143	0.00321	CbGpPWpGaD
Galantamine—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000143	0.000619	CcSEcCtD
Galantamine—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000143	0.000619	CcSEcCtD
Galantamine—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000143	0.000619	CcSEcCtD
Galantamine—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000142	0.000616	CcSEcCtD
Galantamine—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000141	0.000613	CcSEcCtD
Galantamine—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000611	CcSEcCtD
Galantamine—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000611	CcSEcCtD
Galantamine—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000609	CcSEcCtD
Galantamine—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000139	0.000604	CcSEcCtD
Galantamine—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000139	0.000602	CcSEcCtD
Galantamine—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000139	0.000601	CcSEcCtD
Galantamine—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000138	0.0006	CcSEcCtD
Galantamine—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000138	0.000599	CcSEcCtD
Galantamine—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000138	0.000598	CcSEcCtD
Galantamine—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000137	0.000593	CcSEcCtD
Galantamine—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000137	0.000592	CcSEcCtD
Galantamine—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.00059	CcSEcCtD
Galantamine—CHRNA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	0.000136	0.00305	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000136	0.00305	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000135	0.00304	CbGpPWpGaD
Galantamine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000134	0.000583	CcSEcCtD
Galantamine—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000581	CcSEcCtD
Galantamine—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000578	CcSEcCtD
Galantamine—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000133	0.000577	CcSEcCtD
Galantamine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000133	0.000577	CcSEcCtD
Galantamine—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000132	0.00057	CcSEcCtD
Galantamine—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000131	0.000569	CcSEcCtD
Galantamine—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000566	CcSEcCtD
Galantamine—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.00013	0.000564	CcSEcCtD
Galantamine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.00013	0.000564	CcSEcCtD
Galantamine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.00013	0.000562	CcSEcCtD
Galantamine—CHRNG—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	0.00013	0.00291	CbGpPWpGaD
Galantamine—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000129	0.000561	CcSEcCtD
Galantamine—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000129	0.000557	CcSEcCtD
Galantamine—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000556	CcSEcCtD
Galantamine—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000128	0.000556	CcSEcCtD
Galantamine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000127	0.000552	CcSEcCtD
Galantamine—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000127	0.000551	CcSEcCtD
Galantamine—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.000127	0.000858	CbGeAlD
Galantamine—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000548	CcSEcCtD
Galantamine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000126	0.000548	CcSEcCtD
Galantamine—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000126	0.000547	CcSEcCtD
Galantamine—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000126	0.000547	CcSEcCtD
Galantamine—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.000126	0.000546	CcSEcCtD
Galantamine—Constipation—Etoposide—peripheral nervous system neoplasm	0.000125	0.000542	CcSEcCtD
Galantamine—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000125	0.000542	CcSEcCtD
Galantamine—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000538	CcSEcCtD
Galantamine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000124	0.000537	CcSEcCtD
Galantamine—CHRNA4—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000124	0.00279	CbGpPWpGaD
Galantamine—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000124	0.000536	CcSEcCtD
Galantamine—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000534	CcSEcCtD
Galantamine—CHRNA9—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	0.000123	0.00277	CbGpPWpGaD
Galantamine—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000123	0.000531	CcSEcCtD
Galantamine—CHRNE—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	0.000122	0.00274	CbGpPWpGaD
Galantamine—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000527	CcSEcCtD
Galantamine—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000526	CcSEcCtD
Galantamine—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000523	CcSEcCtD
Galantamine—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000121	0.000523	CcSEcCtD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.00012	0.00271	CbGpPWpGaD
Galantamine—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.000522	CcSEcCtD
Galantamine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00012	0.00052	CcSEcCtD
Galantamine—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.000519	CcSEcCtD
Galantamine—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.00012	0.000519	CcSEcCtD
Galantamine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000119	0.000518	CcSEcCtD
Galantamine—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000119	0.000517	CcSEcCtD
Galantamine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000118	0.000512	CcSEcCtD
Galantamine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000118	0.000512	CcSEcCtD
Galantamine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000118	0.00051	CcSEcCtD
Galantamine—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000509	CcSEcCtD
Galantamine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000117	0.000509	CcSEcCtD
Galantamine—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000507	CcSEcCtD
Galantamine—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000506	CcSEcCtD
Galantamine—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000503	CcSEcCtD
Galantamine—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000502	CcSEcCtD
Galantamine—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000116	0.000501	CcSEcCtD
Galantamine—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000116	0.000501	CcSEcCtD
Galantamine—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000501	CcSEcCtD
Galantamine—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000115	0.0005	CcSEcCtD
Galantamine—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000115	0.0005	CcSEcCtD
Galantamine—ACHE—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000115	0.00259	CbGpPWpGaD
Galantamine—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000115	0.000498	CcSEcCtD
Galantamine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000115	0.000497	CcSEcCtD
Galantamine—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000494	CcSEcCtD
Galantamine—Rash—Vincristine—peripheral nervous system neoplasm	0.000114	0.000494	CcSEcCtD
Galantamine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000114	0.000493	CcSEcCtD
Galantamine—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000493	CcSEcCtD
Galantamine—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000492	CcSEcCtD
Galantamine—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000492	CcSEcCtD
Galantamine—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000113	0.00049	CcSEcCtD
Galantamine—Headache—Vincristine—peripheral nervous system neoplasm	0.000113	0.00049	CcSEcCtD
Galantamine—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000488	CcSEcCtD
Galantamine—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000486	CcSEcCtD
Galantamine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000111	0.000483	CcSEcCtD
Galantamine—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000482	CcSEcCtD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.00011	0.00247	CbGpPWpGaD
Galantamine—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000109	0.000474	CcSEcCtD
Galantamine—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000471	CcSEcCtD
Galantamine—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000468	CcSEcCtD
Galantamine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000108	0.000467	CcSEcCtD
Galantamine—CHRNB3—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	0.000108	0.00242	CbGpPWpGaD
Galantamine—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000467	CcSEcCtD
Galantamine—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000465	CcSEcCtD
Galantamine—Nausea—Vincristine—peripheral nervous system neoplasm	0.000107	0.000465	CcSEcCtD
Galantamine—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000464	CcSEcCtD
Galantamine—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000107	0.000464	CcSEcCtD
Galantamine—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000464	CcSEcCtD
Galantamine—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000463	CcSEcCtD
Galantamine—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000463	CcSEcCtD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000107	0.0024	CbGpPWpGaD
Galantamine—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000457	CcSEcCtD
Galantamine—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000456	CcSEcCtD
Galantamine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000105	0.000455	CcSEcCtD
Galantamine—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000455	CcSEcCtD
Galantamine—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000454	CcSEcCtD
Galantamine—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000454	CcSEcCtD
Galantamine—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000452	CcSEcCtD
Galantamine—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000447	CcSEcCtD
Galantamine—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	0.000103	0.00231	CbGpPWpGaD
Galantamine—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000446	CcSEcCtD
Galantamine—CHRNA5—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	0.000102	0.0023	CbGpPWpGaD
Galantamine—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000102	0.00044	CcSEcCtD
Galantamine—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000438	CcSEcCtD
Galantamine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000101	0.00227	CbGpPWpGaD
Galantamine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000101	0.000436	CcSEcCtD
Galantamine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000101	0.000436	CcSEcCtD
Galantamine—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000436	CcSEcCtD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.0001	0.00225	CbGpPWpGaD
Galantamine—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.0001	0.000434	CcSEcCtD
Galantamine—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	9.98e-05	0.000433	CcSEcCtD
Galantamine—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	9.96e-05	0.000432	CcSEcCtD
Galantamine—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	9.91e-05	0.00043	CcSEcCtD
Galantamine—Flushing—Doxorubicin—peripheral nervous system neoplasm	9.91e-05	0.00043	CcSEcCtD
Galantamine—Flatulence—Epirubicin—peripheral nervous system neoplasm	9.9e-05	0.000429	CcSEcCtD
Galantamine—Tension—Epirubicin—peripheral nervous system neoplasm	9.86e-05	0.000427	CcSEcCtD
Galantamine—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	9.84e-05	0.000427	CcSEcCtD
Galantamine—Nervousness—Epirubicin—peripheral nervous system neoplasm	9.76e-05	0.000423	CcSEcCtD
Galantamine—CHRNG—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	9.74e-05	0.00219	CbGpPWpGaD
Galantamine—Back pain—Epirubicin—peripheral nervous system neoplasm	9.72e-05	0.000421	CcSEcCtD
Galantamine—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	9.69e-05	0.00042	CcSEcCtD
Galantamine—Dizziness—Etoposide—peripheral nervous system neoplasm	9.67e-05	0.000419	CcSEcCtD
Galantamine—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	9.66e-05	0.000419	CcSEcCtD
Galantamine—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	9.65e-05	0.000418	CcSEcCtD
Galantamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	9.62e-05	0.00216	CbGpPWpGaD
Galantamine—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	9.54e-05	0.000414	CcSEcCtD
Galantamine—Nausea—Cisplatin—peripheral nervous system neoplasm	9.48e-05	0.000411	CcSEcCtD
Galantamine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	9.47e-05	0.00041	CcSEcCtD
Galantamine—CHRNA9—Neuronal System—HRAS—peripheral nervous system neoplasm	9.44e-05	0.00212	CbGpPWpGaD
Galantamine—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	9.36e-05	0.000406	CcSEcCtD
Galantamine—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	9.32e-05	0.000404	CcSEcCtD
Galantamine—Vomiting—Etoposide—peripheral nervous system neoplasm	9.3e-05	0.000403	CcSEcCtD
Galantamine—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	9.3e-05	0.000403	CcSEcCtD
Galantamine—Anaemia—Epirubicin—peripheral nervous system neoplasm	9.29e-05	0.000403	CcSEcCtD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	9.26e-05	0.00208	CbGpPWpGaD
Galantamine—Agitation—Epirubicin—peripheral nervous system neoplasm	9.23e-05	0.0004	CcSEcCtD
Galantamine—Rash—Etoposide—peripheral nervous system neoplasm	9.22e-05	0.0004	CcSEcCtD
Galantamine—Dermatitis—Etoposide—peripheral nervous system neoplasm	9.21e-05	0.000399	CcSEcCtD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	9.17e-05	0.00206	CbGpPWpGaD
Galantamine—Headache—Etoposide—peripheral nervous system neoplasm	9.16e-05	0.000397	CcSEcCtD
Galantamine—Flatulence—Doxorubicin—peripheral nervous system neoplasm	9.16e-05	0.000397	CcSEcCtD
Galantamine—CHRNE—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	9.16e-05	0.00206	CbGpPWpGaD
Galantamine—Tension—Doxorubicin—peripheral nervous system neoplasm	9.12e-05	0.000395	CcSEcCtD
Galantamine—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	9.1e-05	0.000395	CcSEcCtD
Galantamine—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	9.06e-05	0.00204	CbGpPWpGaD
Galantamine—Malaise—Epirubicin—peripheral nervous system neoplasm	9.06e-05	0.000393	CcSEcCtD
Galantamine—Nervousness—Doxorubicin—peripheral nervous system neoplasm	9.03e-05	0.000391	CcSEcCtD
Galantamine—Vertigo—Epirubicin—peripheral nervous system neoplasm	9.03e-05	0.000391	CcSEcCtD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	9.01e-05	0.00203	CbGpPWpGaD
Galantamine—Syncope—Epirubicin—peripheral nervous system neoplasm	9.01e-05	0.000391	CcSEcCtD
Galantamine—Back pain—Doxorubicin—peripheral nervous system neoplasm	8.99e-05	0.00039	CcSEcCtD
Galantamine—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	8.94e-05	0.000387	CcSEcCtD
Galantamine—ACHE—Metabolism—PPIP5K2—peripheral nervous system neoplasm	8.9e-05	0.002	CbGpPWpGaD
Galantamine—Palpitations—Epirubicin—peripheral nervous system neoplasm	8.88e-05	0.000385	CcSEcCtD
Galantamine—ACHE—Neuronal System—BCHE—peripheral nervous system neoplasm	8.84e-05	0.00199	CbGpPWpGaD
Galantamine—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	8.83e-05	0.000383	CcSEcCtD
Galantamine—Cough—Epirubicin—peripheral nervous system neoplasm	8.77e-05	0.00038	CcSEcCtD
Galantamine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	8.76e-05	0.00038	CcSEcCtD
Galantamine—Convulsion—Epirubicin—peripheral nervous system neoplasm	8.7e-05	0.000377	CcSEcCtD
Galantamine—Nausea—Etoposide—peripheral nervous system neoplasm	8.69e-05	0.000377	CcSEcCtD
Galantamine—Hypertension—Epirubicin—peripheral nervous system neoplasm	8.67e-05	0.000376	CcSEcCtD
Galantamine—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	8.63e-05	0.000374	CcSEcCtD
Galantamine—Anaemia—Doxorubicin—peripheral nervous system neoplasm	8.59e-05	0.000373	CcSEcCtD
Galantamine—Chest pain—Epirubicin—peripheral nervous system neoplasm	8.55e-05	0.000371	CcSEcCtD
Galantamine—Arthralgia—Epirubicin—peripheral nervous system neoplasm	8.55e-05	0.000371	CcSEcCtD
Galantamine—Myalgia—Epirubicin—peripheral nervous system neoplasm	8.55e-05	0.000371	CcSEcCtD
Galantamine—Agitation—Doxorubicin—peripheral nervous system neoplasm	8.54e-05	0.00037	CcSEcCtD
Galantamine—Anxiety—Epirubicin—peripheral nervous system neoplasm	8.52e-05	0.00037	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	8.49e-05	0.000368	CcSEcCtD
Galantamine—Discomfort—Epirubicin—peripheral nervous system neoplasm	8.45e-05	0.000366	CcSEcCtD
Galantamine—Malaise—Doxorubicin—peripheral nervous system neoplasm	8.38e-05	0.000363	CcSEcCtD
Galantamine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	8.37e-05	0.000363	CcSEcCtD
Galantamine—Vertigo—Doxorubicin—peripheral nervous system neoplasm	8.35e-05	0.000362	CcSEcCtD
Galantamine—Syncope—Doxorubicin—peripheral nervous system neoplasm	8.34e-05	0.000361	CcSEcCtD
Galantamine—Confusional state—Epirubicin—peripheral nervous system neoplasm	8.27e-05	0.000358	CcSEcCtD
Galantamine—CHRNB3—Neuronal System—HRAS—peripheral nervous system neoplasm	8.25e-05	0.00186	CbGpPWpGaD
Galantamine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	8.21e-05	0.000356	CcSEcCtD
Galantamine—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	8.17e-05	0.000354	CcSEcCtD
Galantamine—Cough—Doxorubicin—peripheral nervous system neoplasm	8.11e-05	0.000352	CcSEcCtD
Galantamine—Shock—Epirubicin—peripheral nervous system neoplasm	8.07e-05	0.00035	CcSEcCtD
Galantamine—Convulsion—Doxorubicin—peripheral nervous system neoplasm	8.05e-05	0.000349	CcSEcCtD
Galantamine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	8.04e-05	0.000349	CcSEcCtD
Galantamine—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	8.03e-05	0.000348	CcSEcCtD
Galantamine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	8.03e-05	0.000348	CcSEcCtD
Galantamine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	8e-05	0.000347	CcSEcCtD
Galantamine—Skin disorder—Epirubicin—peripheral nervous system neoplasm	7.96e-05	0.000345	CcSEcCtD
Galantamine—BCHE—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.94e-05	0.00179	CbGpPWpGaD
Galantamine—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	7.93e-05	0.000344	CcSEcCtD
Galantamine—Myalgia—Doxorubicin—peripheral nervous system neoplasm	7.91e-05	0.000343	CcSEcCtD
Galantamine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	7.91e-05	0.000343	CcSEcCtD
Galantamine—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	7.91e-05	0.000343	CcSEcCtD
Galantamine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	7.89e-05	0.000342	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	7.86e-05	0.000341	CcSEcCtD
Galantamine—CHRNA5—Neuronal System—HRAS—peripheral nervous system neoplasm	7.82e-05	0.00176	CbGpPWpGaD
Galantamine—Discomfort—Doxorubicin—peripheral nervous system neoplasm	7.82e-05	0.000339	CcSEcCtD
Galantamine—Anorexia—Epirubicin—peripheral nervous system neoplasm	7.82e-05	0.000339	CcSEcCtD
Galantamine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	7.74e-05	0.000336	CcSEcCtD
Galantamine—CHRNA6—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	7.74e-05	0.00174	CbGpPWpGaD
Galantamine—Hypotension—Epirubicin—peripheral nervous system neoplasm	7.66e-05	0.000332	CcSEcCtD
Galantamine—Confusional state—Doxorubicin—peripheral nervous system neoplasm	7.65e-05	0.000332	CcSEcCtD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	7.55e-05	0.0017	CbGpPWpGaD
Galantamine—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	7.47e-05	0.000324	CcSEcCtD
Galantamine—Shock—Doxorubicin—peripheral nervous system neoplasm	7.46e-05	0.000324	CcSEcCtD
Galantamine—CHRNG—Neuronal System—HRAS—peripheral nervous system neoplasm	7.46e-05	0.00168	CbGpPWpGaD
Galantamine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	7.44e-05	0.000323	CcSEcCtD
Galantamine—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	7.43e-05	0.000322	CcSEcCtD
Galantamine—Insomnia—Epirubicin—peripheral nervous system neoplasm	7.42e-05	0.000322	CcSEcCtD
Galantamine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	7.4e-05	0.000321	CcSEcCtD
Galantamine—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	7.37e-05	0.000319	CcSEcCtD
Galantamine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	7.36e-05	0.000319	CcSEcCtD
Galantamine—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	7.33e-05	0.000318	CcSEcCtD
Galantamine—Somnolence—Epirubicin—peripheral nervous system neoplasm	7.29e-05	0.000316	CcSEcCtD
Galantamine—Anorexia—Doxorubicin—peripheral nervous system neoplasm	7.23e-05	0.000314	CcSEcCtD
Galantamine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	7.22e-05	0.000313	CcSEcCtD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	7.21e-05	0.00162	CbGpPWpGaD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	7.13e-05	0.0016	CbGpPWpGaD
Galantamine—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	7.13e-05	0.000309	CcSEcCtD
Galantamine—CHRNB2—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	7.09e-05	0.00159	CbGpPWpGaD
Galantamine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	7.09e-05	0.000307	CcSEcCtD
Galantamine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	7.08e-05	0.000307	CcSEcCtD
Galantamine—Fatigue—Epirubicin—peripheral nervous system neoplasm	7.07e-05	0.000306	CcSEcCtD
Galantamine—CHRNE—Neuronal System—HRAS—peripheral nervous system neoplasm	7.02e-05	0.00158	CbGpPWpGaD
Galantamine—Constipation—Epirubicin—peripheral nervous system neoplasm	7.01e-05	0.000304	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	6.91e-05	0.0003	CcSEcCtD
Galantamine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	6.86e-05	0.000297	CcSEcCtD
Galantamine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	6.81e-05	0.000295	CcSEcCtD
Galantamine—CHRNB2—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	6.81e-05	0.00153	CbGpPWpGaD
Galantamine—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	6.76e-05	0.000293	CcSEcCtD
Galantamine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	6.74e-05	0.000292	CcSEcCtD
Galantamine—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	6.7e-05	0.000291	CcSEcCtD
Galantamine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	6.68e-05	0.00029	CcSEcCtD
Galantamine—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	6.6e-05	0.000286	CcSEcCtD
Galantamine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	6.55e-05	0.000284	CcSEcCtD
Galantamine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	6.54e-05	0.000284	CcSEcCtD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	6.52e-05	0.00147	CbGpPWpGaD
Galantamine—Constipation—Doxorubicin—peripheral nervous system neoplasm	6.49e-05	0.000281	CcSEcCtD
Galantamine—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	6.48e-05	0.000281	CcSEcCtD
Galantamine—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	6.48e-05	0.000281	CcSEcCtD
Galantamine—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	6.25e-05	0.000271	CcSEcCtD
Galantamine—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	6.2e-05	0.000269	CcSEcCtD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	6.19e-05	0.00139	CbGpPWpGaD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	6.13e-05	0.00138	CbGpPWpGaD
Galantamine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	6.04e-05	0.000262	CcSEcCtD
Galantamine—ACHE—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.01e-05	0.00135	CbGpPWpGaD
Galantamine—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	6e-05	0.00026	CcSEcCtD
Galantamine—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	6e-05	0.00026	CcSEcCtD
Galantamine—CHRNA6—Neuronal System—HRAS—peripheral nervous system neoplasm	5.93e-05	0.00133	CbGpPWpGaD
Galantamine—Asthenia—Epirubicin—peripheral nervous system neoplasm	5.88e-05	0.000255	CcSEcCtD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	5.82e-05	0.00131	CbGpPWpGaD
Galantamine—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	5.61e-05	0.000243	CcSEcCtD
Galantamine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	5.59e-05	0.000242	CcSEcCtD
Galantamine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	5.44e-05	0.000236	CcSEcCtD
Galantamine—Dizziness—Epirubicin—peripheral nervous system neoplasm	5.42e-05	0.000235	CcSEcCtD
Galantamine—CHRND—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	5.42e-05	0.00122	CbGpPWpGaD
Galantamine—BCHE—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.37e-05	0.00121	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	5.36e-05	0.00121	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—HRAS—peripheral nervous system neoplasm	5.22e-05	0.00117	CbGpPWpGaD
Galantamine—Vomiting—Epirubicin—peripheral nervous system neoplasm	5.21e-05	0.000226	CcSEcCtD
Galantamine—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	5.19e-05	0.000225	CcSEcCtD
Galantamine—Rash—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.000224	CcSEcCtD
Galantamine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.000224	CcSEcCtD
Galantamine—Headache—Epirubicin—peripheral nervous system neoplasm	5.14e-05	0.000223	CcSEcCtD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—peripheral nervous system neoplasm	5.05e-05	0.00113	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	5.05e-05	0.00113	CbGpPWpGaD
Galantamine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	5.02e-05	0.000218	CcSEcCtD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5e-05	0.00112	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	4.9e-05	0.0011	CbGpPWpGaD
Galantamine—Nausea—Epirubicin—peripheral nervous system neoplasm	4.87e-05	0.000211	CcSEcCtD
Galantamine—Vomiting—Doxorubicin—peripheral nervous system neoplasm	4.82e-05	0.000209	CcSEcCtD
Galantamine—Rash—Doxorubicin—peripheral nervous system neoplasm	4.78e-05	0.000207	CcSEcCtD
Galantamine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	4.78e-05	0.000207	CcSEcCtD
Galantamine—Headache—Doxorubicin—peripheral nervous system neoplasm	4.75e-05	0.000206	CcSEcCtD
Galantamine—CHRNA7—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	4.65e-05	0.00105	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	4.61e-05	0.00104	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	4.58e-05	0.00103	CbGpPWpGaD
Galantamine—Nausea—Doxorubicin—peripheral nervous system neoplasm	4.51e-05	0.000195	CcSEcCtD
Galantamine—CHRNA2—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	4.38e-05	0.000984	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GNS—peripheral nervous system neoplasm	4.35e-05	0.000978	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—BCHE—peripheral nervous system neoplasm	4.32e-05	0.000971	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NME1—peripheral nervous system neoplasm	4.17e-05	0.000937	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—HRAS—peripheral nervous system neoplasm	4.15e-05	0.000933	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—HRAS—peripheral nervous system neoplasm	4.11e-05	0.000924	CbGpPWpGaD
Galantamine—ACHE—Metabolism—COX2—peripheral nervous system neoplasm	4.01e-05	0.000902	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GNS—peripheral nervous system neoplasm	3.88e-05	0.000872	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	3.79e-05	0.000853	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—HRAS—peripheral nervous system neoplasm	3.76e-05	0.000845	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NME1—peripheral nervous system neoplasm	3.72e-05	0.000836	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.65e-05	0.000821	CbGpPWpGaD
Galantamine—BCHE—Metabolism—COX2—peripheral nervous system neoplasm	3.58e-05	0.000805	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	3.58e-05	0.000804	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—HRAS—peripheral nervous system neoplasm	3.57e-05	0.000802	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—HRAS—peripheral nervous system neoplasm	3.53e-05	0.000793	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—HRAS—peripheral nervous system neoplasm	3.35e-05	0.000754	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	2.94e-05	0.00066	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—HRAS—peripheral nervous system neoplasm	2.91e-05	0.000654	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	2.71e-05	0.000609	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ENO2—peripheral nervous system neoplasm	2.63e-05	0.000592	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	2.48e-05	0.000557	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.47e-05	0.000555	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	2.41e-05	0.000543	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.39e-05	0.000537	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ENO2—peripheral nervous system neoplasm	2.35e-05	0.000528	CbGpPWpGaD
Galantamine—ACHE—Metabolism—BCHE—peripheral nervous system neoplasm	2.23e-05	0.0005	CbGpPWpGaD
Galantamine—ACHE—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.12e-05	0.000477	CbGpPWpGaD
Galantamine—ACHE—Metabolism—TH—peripheral nervous system neoplasm	2.09e-05	0.000471	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—HRAS—peripheral nervous system neoplasm	2.07e-05	0.000466	CbGpPWpGaD
Galantamine—BCHE—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.89e-05	0.000426	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TH—peripheral nervous system neoplasm	1.87e-05	0.00042	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—HRAS—peripheral nervous system neoplasm	1.85e-05	0.000416	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	1.78e-05	0.000401	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.71e-05	0.000384	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GNAS—peripheral nervous system neoplasm	1.71e-05	0.000384	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ABCB1—peripheral nervous system neoplasm	1.68e-05	0.000377	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	1.65e-05	0.00037	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.61e-05	0.000363	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GNAS—peripheral nervous system neoplasm	1.52e-05	0.000343	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ABCB1—peripheral nervous system neoplasm	1.5e-05	0.000336	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.17e-05	0.000262	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1.12e-05	0.000251	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	1.08e-05	0.000243	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	1.08e-05	0.000242	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	9.13e-06	0.000205	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.71e-06	0.000196	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	8.58e-06	0.000193	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	7.06e-06	0.000159	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	7.01e-06	0.000158	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	6.88e-06	0.000155	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	5.97e-06	0.000134	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.69e-06	0.000128	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	5.61e-06	0.000126	CbGpPWpGaD
Galantamine—ACHE—Metabolism—AKT1—peripheral nervous system neoplasm	4.61e-06	0.000104	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	4.58e-06	0.000103	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	4.5e-06	0.000101	CbGpPWpGaD
Galantamine—BCHE—Metabolism—AKT1—peripheral nervous system neoplasm	4.11e-06	9.25e-05	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.89e-06	4.25e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.24e-06	2.78e-05	CbGpPWpGaD
